GDP-Mannose Inhibitor Development Service

GDP-Mannose Inhibitor Development Service

GDP-Mannose Inhibitor Development Service at CD BioGlyco

The biosynthesis of mannose-rich glycoconjugates requires the conversion of monosaccharides into activated sugar nucleotides, which requires multiple enzyme catalysis, such as GDP-mannose pyrophosphorylase (GDP-MP), phosphomannomutase (PMM), dolichol phosphate-mannose synthase (DPMS), and phosphomannose isomerase (PMI). The sequential action of PMM and GDP-MP converts mannose-6-phosphate (M-6-P) into GDP-mannose. GDP-Mannose is an important glycosylation substrate and plays a vital role in the glycosylation process. By developing GDP-Mannose inhibitors, we interfere with glycosylation reactions, regulating cell surface glycosylation modifications, thereby affecting a variety of biological processes and related diseases.

CD BioGlyco has established diverse Glycosylation Inhibitor Development solutions and provides professional GDP-mannose inhibitor development services. The service contents are as follows:

  • High-throughput screening (HTS)

GDP-MP is an important enzyme in the biosynthesis of mannose-containing complex sugars, which is applied as a target for the development of new inhibitors. CD BioGlyco has a self-built small molecule chemical library. We have developed a highly sensitive, multi-well plate-based enzyme activity assay method that uses phosphate detection technology to conduct HTS of the small molecule chemical library to identify GDP-MP inhibitors and screen potential inhibitor candidates.

  • Identification of active compounds

CD BioGlyco re-confirms the screened compounds through GDP-MP assay and counter-screening assay technology to avoid false positive results. After identifying the GDP-MP inhibitors, we perform a dose-response assay to quantify the compound's IC50 and thereby determine its inhibitory potency.

  • Inhibitory activity evaluation

CD BioGlyco evaluates the inhibitory activity of compounds based on the inhibitory potency of each GDP-MP inhibitor using appropriate biological and biochemical experimental techniques, including in vitro and in vivo cell experiments.

  • Structural optimization and modification

CD BioGlyco uses structure-activity relationship analysis and medicinal chemistry methods to optimize and modify the structure of existing GDP-mannose inhibitors to improve their activity, selectivity, and pharmacokinetic properties. We have developed some GDP-MP inhibitors, such as 4-pyrazin-4-ylquinolines, 2-substituted quinolines, alkyl-resorcinol derivatives, etc.

GDP-Mannose inhibitor development service. Fig.1 GDP-Mannose inhibitor development service. (CD BioGlyco)


Technology: HTS

Journal: Antimicrobial Agents and Chemotherapy

IF: 5.938

Published: 2010

Results: Since Leishmania synthesizes mannose-rich glycoconjugates, the authors used HTS technology to develop new anti-Leishmania compounds based on the principle that GDP-MP inhibitors inhibit GDP-mannose production. Twenty compounds were obtained through HTS, and the anti-Leishmania activity of the obtained compounds was evaluated in promastigote-infected macrophages. The results indicated that compound 3 had an obvious inhibitory effect, which belonged to the 4-pyrazin-4-ylquinoline class and was selectively toxic to Leishmania amastigotes.

Treatment of Leishmania major-infected mouse macrophages with GDP-MP inhibitors. Fig.2 Treatment of Leishmania major-infected mouse macrophages with GDP-MP inhibitors. (Lackovic, et al., 2010)


  • Antiviral drug development: GDP-Mannose is an important glycosylation substrate that plays a vital role in viral infection and replication. The development of GDP-mannose inhibitors interferes with the glycosylation process of the virus, thereby inhibiting the growth and spread of the virus, and providing a new direction for the development of antiviral drugs.
  • Anti-cancer research: Glycosylation modifications on the surface of tumor cells are closely related to tumor invasion and metastasis. By developing GDP-mannose inhibitors, we interfere with the glycosylation process of tumor cells, inhibit their invasion and metastasis capabilities, and provide new strategies and drug targets for anti-cancer research.
  • Sugar metabolism research: GDP-mannose plays an important role in the process of sugar metabolism, such as the synthesis of a variety of glycosylation molecules and glycopeptides. The development of GDP-mannose inhibitors interferes with the glucose metabolism pathway to study the pathological mechanisms of diabetes, congenital glucose metabolism disorders, and other diseases.


  • CD BioGlyco provides mature structure optimization and modification services to existing GDP-mannose inhibitors to improve their activity and selectivity.
  • CD BioGlyco provides custom GDP-mannose inhibitor development strategies based on the client's research goals and project requirements, from compound screening to mechanism research and preclinical evaluation, designing and executing suitable experimental plans.
  • CD BioGlyco combines a variety of technology means, including HTS, molecular modeling, molecular biology, and cell biology, to evaluate and optimize the activity and pharmacokinetic properties of candidate GDP-mannose inhibitors from multiple angles and levels.

CD BioGlyco is a leading biotechnology company in the world. We closely follow the development of science and technology, master the latest research progress and technological applications, and carry out the GDP-mannose inhibitors development in an efficient and precise manner. Please feel free to contact us if you would like to inquire about detailed development services.


  1. Lackovic, K.; et al. Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library. Antimicrobial Agents and Chemotherapy. 2010, 54(5): 1712-1719.
  2. Levaique, H.; et al. Alkyl-resorcinol derivatives as inhibitors of GDP-mannose pyrophosphorylase with antileishmanial activities. Molecules. 2021, 26(6): 1551.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.